← Back to Search

Multidisciplinary Team Care for Breast Cancer (TITAN Trial)

Phase 2
Waitlist Available
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
histologically confirmed malignancy (breast or lymphoma);
scheduled to receive anthracycline and/or trastuzumab-based chemotherapy;
Must not have
previous radiotherapy to thorax.
previous anthracycline or trastuzumab-based therapy;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 12 months
Awards & highlights

Summary

This trial will assess whether receiving extra assessments and early interventions from teams of health care professionals is helpful for people diagnosed with cancer.

Who is the study for?
This trial is for adults over 18 with breast cancer or lymphoma, scheduled for specific chemotherapy treatments, and able to attend follow-ups. It's not for those with heart issues, prior thorax radiotherapy, previous similar chemo treatments, physical disability impeding certain tests, psychiatric conditions affecting consent, or involvement in related studies.Check my eligibility
What is being tested?
The TITAN Study is testing whether extra care from a team of various health professionals (like nurses and dietitians) can benefit people with cancer during and after treatment. Participants will be randomly assigned to receive either this multidisciplinary intervention or the usual care.See study design
What are the potential side effects?
Since this study focuses on additional assessments rather than medication side effects are not the main concern; however, any interventions introduced by the multidisciplinary team may carry their own risks depending on individual patient circumstances.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer (breast or lymphoma) has been confirmed through tissue examination.
Select...
I am scheduled for chemotherapy that includes anthracycline or trastuzumab.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had radiation therapy to my chest area before.
Select...
I have had treatments with anthracycline or trastuzumab.
Select...
I do not have heart failure, cardiomyopathy, or an LVEF below 50%.
Select...
I have a physical disability that prevents me from undergoing exercise tests or DEXA scans.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
cardiac MRI
Secondary outcome measures
serum biomarkers
Other outcome measures
multidisciplinary team interventions

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: multidisciplinary team interventionExperimental Treatment1 Intervention
Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
Group II: Observational armActive Control1 Intervention
Participants randomized to observational arm will receive usual care.

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
901 Previous Clinical Trials
387,470 Total Patients Enrolled
13 Trials studying Breast Cancer
2,203 Patients Enrolled for Breast Cancer

Media Library

Multidisciplinary team intervention Clinical Trial Eligibility Overview. Trial Name: NCT01621659 — Phase 2
Breast Cancer Research Study Groups: Observational arm, multidisciplinary team intervention
Breast Cancer Clinical Trial 2023: Multidisciplinary team intervention Highlights & Side Effects. Trial Name: NCT01621659 — Phase 2
Multidisciplinary team intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT01621659 — Phase 2
~7 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top